Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NeuroElevate Biosciences is an Australian biotechnology company dedicated to transforming paediatric neurodevelopmental care through innovative therapeutic solutions. Founded in 2024 by paediatrician Dr. Natasha Macko, the company focuses on improving the safety and efficacy of treatments for conditions such as Autism Spectrum Disorder (ASD), ADHD, and intellectual disabilities. Their lead development programs utilize research-driven applications of cannabidiol (CBD) and melatonin, currently being evaluated in a Phase 2 clinical trial for ASD. NeuroElevate Biosciences aims to bridge the gap between clinical research and real-world patient needs, ensuring their therapies meet rigorous regulatory standards while enhancing the quality of life for children and their families.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NeuroElevate Biosciences.